Support for a new class of Diabetes Drugs


An article titled “Study provides additional support for use of new class of diabetes drugs” was recently released and it discusses a new study led by a cardiologist from Brigham and Women’s Hospital that has assessed the cardiovascular and renal outcomes for ertugliflozin, an SGLT2 inhibitor prescribed for patients with type 2 diabetes, helping them control blood sugar levels. recently published an article titled: 3 top diabetes stocks for the 2nd half of 2020

The article states: “Numerous companies are hard at work developing diabetes treatments and tools that relieve the pain of this deadly disease. DexCom (NASDAQ: DXCM), Livongo Health (NASDAQ: LVGO), and Tandem Diabetes Care (NASDAQ: TNDM) are three companies involved in diabetes care that you should keep an eye on as we transition to the second half of 2020.

The fact is today, more than 100 million U.S. adults are now living with diabetes or prediabetes, according to a new report released by the Centers for Disease Control and Prevention (CDC).

Specialized diabetic nutrition is a key growth area. Take a look at Glucose Health, Inc. (OTC Pink: GLUC). GLUC manufacturers nutritional beverages for the adult-diabetic nutrition consumer retail category under the registered trademark GLUCODOWN®. 

Despite being on the shelves of national retailers lik eWalmart (NYSE: WMT), CVS Health (NYSE: CVS) and online at (NASDAQ: AMZN), GLUC is still trading below a $30 million valuation.

GLUCODOWN® is infused with a special form of diabetic fiber demonstrated in more than 20 clinical studies to help maintain healthy blood sugar levels and regular digestive health.

See the latest GLUCODOWN® products here;

Glucose Health, Inc. (OTC Pink: GLUC) just announced unprecedented consumer demand and 2nd quarter fiscal 2020 revenues, which increased 186% compared to the 2nd quarter of fiscal 2019 – in fact, Q2 2020 revenues were just $7,140 short of tripling 2nd quarter 2019 revenues.

What are the revenues of this company going to look like when the latest GLUCODOWN® numbers are reported for Q3 and Q4? 

Over the past 12 months, GLUC has seen a range of approximately $.20 – $1.90 per share and with only 12.5 million shares outstanding, GLUC could be the best value in the diabetes space and should be on everybody’s watch list. 

About is a leading independent small cap media portal with an extensive history of providing unparalleled content for the Emerging Growth markets and companies. Through its evolution, found a niche in identifying companies that can be overlooked by the markets due to, among other reasons, trading price or market capitalization. We look for strong management, innovation, strategy, execution, and the overall potential for long- term growth. Aside from being a trusted resource for the Emerging Growth info-seekers, we are well known for discovering undervalued companies and bringing them to the attention of the investment community. Through our parent Company, we also have the ability to facilitate road shows to present your products and services to the most influential investment banks in the space.

All information contained herein as well as on the website is obtained from sources believed to be reliable but not guaranteed to be accurate or all-inclusive. All material is for informational purposes only, is only the opinion of and should not be construed as an offer or solicitation to buy or sell securities. The information includes certain forward-looking statements, which may be affected by unforeseen circumstances and / or certain risks.  This report is not without bias. has motivation by means of either self-marketing or has been compensated by or for a company or companies discussed in this article. has been compensated twelve thousand one hundred dollars in consideration for its work with Glucose Health, Inc. through the date this was published. may or may not receive additional compensation, details about which can be found in our full disclosure, which can be found here  You can easily loose money investing in highly speculative small cap stocks like the ones mentioned within. Please consult an investment professional before investing in anything viewed within. When is long shares it will sell those shares. In addition, please make sure you read and understand the Terms of Use, Privacy Policy and the Disclosure posted on the website.